期刊文献+

Influence of Simvastatin for In-stent Restenosis Rate and Blood Lipid Level and Inflammation Actor after Coronary Artery Stent Implantation

Influence of Simvastatin for In-stent Restenosis Rate and Blood Lipid Level and Inflammation Actor after Coronary Artery Stent Implantation
下载PDF
导出
摘要 Objectives To investigate the effect of simvastatin on the probability of restenosis after stent implantation and serum level of lipids as well as high-sensitivity C-reactive protein (hs-CRP) in patients with coronary heart disease (CHD). Methods 118 patients with CHD after stenting therapy were divided into treatment group (n=62) and control group (n=56) randomly. All patients were treated with aspirin (100 mg/d) and clopidogrel (75 mg/d) while treatment group patients took simvastatin (40 mg qn) additionally. All patients underwent coronary angiography (CAG) to compare the difference of restenosis and the serum level of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-c), high-density lipoprotein cholesterol (HDL-c), triglyceride (TG) as well as hs-CRP after the drug treatment for 6 months. Results The probability of restenosis was significantly lower in the treatment group than that of control group (P<0.01) and the results were similar between the patients with bare metal stent (P<0.01) and those with sirolimus-eluting stent (P<0.01). The serum levels of TC (P<0.01), LDL-c (P<0.01), TG (P<0.05) and hs-CRP (P<0.01) were obviously lower while the HDL-c (P<0.05) level was higher in the treatment group than those of control group. There was no death case. Conclusions Simvastatin could decrease the probability of restenosis significantly after coronary stent implantation with dose of 40 mg/d. It also has good performance on lipids control and lightening inflammatory reactions with its undoubtedly safety. Objectives To investigate the effect of simvastatin on the probability of restenosis after stent implantation and serum level of lipids as well as high-sensitivity C-reactive protein (hs-CRP) in patients with coronary heart disease (CHD). Methods 118 patients with CHD after stenting therapy were divided into treatment group (n=62) and control group (n=56) randomly. All patients were treated with aspirin (100 mg/d) and clopidogrel (75 mg/d) while treatment group patients took simvastatin (40 mg qn) additionally. All patients underwent coronary angiography (CAG) to compare the difference of restenosis and the serum level of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-c), high-density lipoprotein cholesterol (HDL-c), triglyceride (TG) as well as hs-CRP after the drug treatment for 6 months. Results The probability of restenosis was significantly lower in the treatment group than that of control group (P<0.01) and the results were similar between the patients with bare metal stent (P<0.01) and those with sirolimus-eluting stent (P<0.01). The serum levels of TC (P<0.01), LDL-c (P<0.01), TG (P<0.05) and hs-CRP (P<0.01) were obviously lower while the HDL-c (P<0.05) level was higher in the treatment group than those of control group. There was no death case. Conclusions Simvastatin could decrease the probability of restenosis significantly after coronary stent implantation with dose of 40 mg/d. It also has good performance on lipids control and lightening inflammatory reactions with its undoubtedly safety.
出处 《South China Journal of Cardiology》 CAS 2007年第3期135-137,共3页 岭南心血管病杂志(英文版)
关键词 SIMVASTATIN stent restenosis LIPIDS high-sensitivity C-reactive protein simvastatin stent restenosis lipids high-sensitivity C-reactive protein
  • 相关文献

参考文献7

  • 1Gaoyun-lin.Apply of Statins on patients with acute coronary syn- dromes[].Chinese Journal of Cardiology.2003
  • 2Farnier M.Combination therapy with an HMG-CoA reductase in- hibitor and a fibric acid derivative[].American Journal of Cardiovascular Drugs.2003
  • 3Andersen H,Maeng M,Thorwest M, et al.Constrictive vascu- lar remodeling rather than neointimal formation explains luminal narrowing after deep vessel wall injury Insights from a new por- cine coronary restenosis model[].Circulation.1995
  • 4Dussaillant GR,Mintz GS,Pilchard AD, et al.Small stent size and intimal hyperplasia contribute to restenosis: A volumetric in- travascular ultrasound analysis[].Journal of the American College of Cardiology.1995
  • 5Reimers B,Monssa I,Akiyama T,et al.Long-term clinical follow-up after successful repeat percutaneous intervention for stent restenosis[].Journal of the American College of Cardiology.1997
  • 6Martin G,Duez H,Blanquart C,et al.Statin-induced inhibition of the Rho-signaling pathway activates PPARa and induces HDL apoA-i[].The Journal of Clinical Investigation.2001
  • 7Takebayashi H,Mintz GS,Carlier SG,et al.Nonuniform strut distribution correlates with more neointimal hyperplasia after sirolimus-eluting stent implantation[].Circulation.2004

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部